Please ensure Javascript is enabled for purposes of website accessibility

3 Things About Teladoc That Smart Investors Know

By Jason Hawthorne – Aug 25, 2021 at 6:10AM

Key Points

  • Not all telehealth is created equal.
  • The company’s strategy has been consistent.
  • It’s important to pay attention to which stakeholders are winning.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's building a virtual healthcare journey.

One of the early adaptations during the pandemic was a shift to virtual care. Many healthcare companies touted their virtual services while others quickly developed an application to get in the game. It was a radical change to an industry that had been slowly advancing for the past decade.

Teladoc Health (TDOC -3.40%) became synonymous with telemedicine, and the stock rocketed to an all-time high. But it's been a tough slog since the peak. A bevy of competition and an enormous acquisition have Wall Street questioning its prospects. The stock is down 52% since February. Here's what analysts might be getting wrong -- and right -- about the path forward.

A patient having a virtual visit with a doctor through a tablet.

Image source: Getty Images.

Competition is in the eye of the beholder 

At first glance, it looks like Teladoc is surrounded on by companies waiting to take market share. A closer look reveals the bark may be worse than the bite for many would-be competitors.

Amwell (AMWL -2.88%) went public last fall with a $100 million investment from Alphabet's Google Cloud division. It hasn't been a great first year as a public company. The stock is down 55% from the initial public offering (IPO). In its most recent quarter, total visits and active providers were down 19% and 12%, respectively, from the same quarter last year. That's abysmal compared to Teladoc, which saw visits rise 28% year over year in the same period.

Doximity (DOCS -2.29%) recently provided its latest update for the quarter ending in June. It isn't so much a direct competitor -- it's a kind of LinkedIn for clinicians -- as a platform with some overlapping functionality. It launched a video dialer service in May 2020 that helped physicians on the platform conduct virtual visits. Although the company saw revenue grow 100% year over year, virtual visits per provider dropped. It was the result of implementing a paywall after the service was initially free at the beginning of the pandemic.

Finally, Amazon.com (AMZN -0.77%) confirmed in March that it would roll out its internal healthcare app to all of its employees, as well as other companies. It could prove to be the most direct competitor for Teladoc. It offers a wide range of services, including primary and urgent care. Other competitors -- beyond Amazon -- have either been acquired or combined in an effort to broaden their services.

Teladoc CEO Jason Gorevic doesn't seem concerned. In the company's first-quarter earnings call, he pointed to the breadth of offerings across the entire healthcare journey, in addition to the various types of healthcare companies in its customer base, to highlight Teladoc's advantages. Those comments seem to be validated by second-quarter results, when he announced that over 75% of new business was for multiple products. That compares with about 50% in the same quarter last year. 

Recent acquisitions are nothing new

Many on Wall Street couldn't believe their ears when Teladoc announced it was buying Livongo last August for $18.5 billion. The final price tag was less, after both companies' shares fell in the aftermath. Still, it was an enormous deal that essentially doubled the size of the company. But those who have been watching Teladoc for years know it was nothing new. It has made a habit of building its business through acquisitions -- even if they were much smaller.

Year Acquisition Amount Reason
2020 Livongo $13.9 billion Digital chronic care management
2020 InTouch Health $1.07 billion Telehealth for hospitals and health systems
2019 Vida Health $5 million Investment in chronic are management company
2019 MedecinDirect $11.2 International Expansion
2018 Advance Medical $351.7 million International Expansion
2017 Best Doctors $445.5 million High-acuity, complex case consultation

Data source: Teladoc.

All told, the company has spent $15.8 billion on acquisitions in the past few years and currently sits with a market capitalization of $23 billion. That's not a ringing endorsement of the deals. Despite increasing the size of the business and its offerings, the company still isn't cash flow positive. For that reason, the jury is still out on whether the strategy is working.

The business can be successful even if investors aren't

It's clear that Teladoc is expanding its offerings throughout the healthcare system. Through the years, it has built on the basic virtual health platform and added inpatient care, chronic disease management, and both primary and specialty care. It is slowly creating an end-to-end alternative to traditional in-person healthcare experiences. In doing so, it is adding value to patients and providers by increasing convenience and reducing costs. It sounds marvelous. Except it's coming at a price.

The company went public in the middle of 2015, and shares have risen 411% since. And while revenue has jumped 1,400% since 2016, the number of shares outstanding is up 264%. Financials are only available going back to 2013. But the only year the company has had positive operating cash flow was 2019. That means something has to give.

Gorevic and company will no doubt spend the next few years digesting past acquisitions and trying to refine how each service integrates with the others to create a compelling value proposition. If shareholders are going to realize the benefits, some of the top-line growth needs to start paying off. The company has plenty of cash, but Wall Street isn't likely to give it credit for its potential unless it can prove it has a path to eventual profitability. It's just another thing smart investors know and will be looking for in the quarters ahead.

John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Jason Hawthorne owns shares of Amazon and Teladoc Health. The Motley Fool owns shares of and recommends Alphabet (A shares), Alphabet (C shares), Amazon, Amwell, and Teladoc Health. The Motley Fool recommends the following options: long January 2022 $1,920 calls on Amazon and short January 2022 $1,940 calls on Amazon. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Teladoc Health Stock Quote
Teladoc Health
TDOC
$27.60 (-3.40%) $0.97
Amazon Stock Quote
Amazon
AMZN
$93.41 (-0.77%) $0.72
Alphabet (A shares) Stock Quote
Alphabet (A shares)
GOOGL
$97.46 (-1.02%) $-1.00
Alphabet (C shares) Stock Quote
Alphabet (C shares)
GOOG
$97.60 (-1.24%) $-1.22
Amwell Stock Quote
Amwell
AMWL
$3.71 (-2.88%) $0.11
Doximity, Inc. Stock Quote
Doximity, Inc.
DOCS
$31.65 (-2.29%) $0.74

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.